2022-502539-21-00招募中3 期
An Open-Label Uncontrolled Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Activity of Nipocalimab in Children Aged 2 to less than 18 years with Generalized Myasthenia Gravis
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 3
- 试验地点
- 2
- 主要终点
- The effect of nipocalimab on total serum IgG in pediatric participants 2 to <18 years of age with gMG who have an insufficient clinical response to ongoing, stable standard-of-care therapy.
研究概览
简要总结
To evaluate the efficacy, safety, tolerability, and pharmacokinetics of nipocalimab in children and adolescents (2 to 17) with gMG who have an insufficient clinical response to ongoing, stable standard-of-care therapy
入排标准
- 年龄范围
- 0 years 至 17 years（0-17 Years）
- 接受健康志愿者
- 是
入选标准
- •2 to <18 years of age.
- •Diagnosis of MG with generalized muscle weakness meeting the clinical criteria for gMG as defined by the MGFA Clinical Classification Class IIa/b, IIIa/b, or IVa/b at screening
- •Has a positive serologic test for acetylcholine receptor (anti-AChR) antibodies or muscle-specific tyrosine kinase (anti-MuSK) antibodies at screening.
- •Has suboptimal response to current stable therapy(as defined in the protocol) for gMG according to the investigator.
- •Participants who have undergone splenectomy (if local regulatory authority has not requested exclusion of participants with splenectomy) must be at least 3 months post resection prior to screening and must be vaccinated as per the United States Center for Disease Control and Prevention annual Recommended Immunization Schedule for ages 18 years or younger, United States OR must be vaccinated as per country/territory-specific guidelines or local regulations. Note: This criterion is not applicable if splenectomy is excluded by the local authority.
- •Is recommended to be up to date on all age-appropriate vaccinations (eg diphtheria and tetanus) prior to screening as per routine local medical guidelines. It is strongly recommended that participants, as applicable, will have completed a locally approved (or emergency useauthorized) COVID-19 vaccination regimen and it should be at least 2 weeks prior to study related visits or procedures. Study participants should follow applicable local vaccine labeling, guidelines, and standards-of-care for patients receiving immune-targeted therapy when determining an appropriate interval between vaccination and study enrollment
- •A female of childbearing potential must have a negative highly sensitive serum at Screening and a negative urine pregnancy test at Day 1 prior to administration of study intervention.
- •Additional Inclusion criteria are included in the protocol
排除标准
- •Has a history of severe and/or uncontrolled hepatic (eg, viral/alcoholic/autoimmune hepatitis/cirrhosis and/or metabolic liver disease), gastrointestinal, renal, pulmonary, cardiovascular (including congenital heart diseases), psychiatric, neurological musculoskeletal disorder, any other medical disorder(s) (eg, diabetes mellitus), risk factors for thrombosis events (eg, a history of VTE or antiphospholipid syndrome, or a personal or family history of heritable coagulation disorder such as Factor V Leiden, Protein S or Protein C deficiency, atrial fibrillation/flutter, major orthopedic surgery or significant trauma that may increase the risk of VTE, is expected to be immobilized for prolonged periods of time), or has clinically significant abnormalities in screening laboratory, that might interfere with participant's full participation in the study, and/or might jeopardize the safety of the participant or the validity of the study results.
- •Has shown a previous severe immediate hypersensitivity reaction, such as anaphylaxis to therapeutic proteins (eg, monoclonal antibodies).
- •Has experienced myocardial infarction, unstable ischemic heart disease, or stroke within 12 weeks of screening
- •History of moderate or severe substance or alcohol use disorder according to Diagnostic and Statistical Manual of Mental Disorders (5th edition) (DSM-5) criteria, except nicotine or caffeine, within 1 year before Screening.
- •Is currently taking eculizumab or other novel immune agents, IgG Fcrelated protein therapeutics, or Fc- conjugated therapeutic agents, including factor or enzyme replacement.
- •Has received, rituximab within 6 months prior to first administration of study intervention.
- •Has received or is expected to receive a live vaccine within 4 weeks prior to screening or has a known need to receive a live vaccine during the study, or within 8 weeks after the last administration of study intervention. For the Bacille Calmette-Guerin (BCG) vaccine, see exclusion criterion
- •Participants are allowed to receive a vaccine conditionally approved by their regional health advisory for emergency use for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), unless it is a live vaccine. Concomitant enrollment in an investigational trial for any SARS-CoV-2 (COVID-19) vaccine while participating in this study is not permitted.
- •Has received plasmapheresis, immunoadsorption therapy, or IVIg within 4 weeks prior to baseline.
- •Has another medical condition that requires oral or parenteral corticosteroids unless the dose has been stable for at least 4 weeks prior to baseline and is expected to remain stable during the study. Inhaled, intra-articular, topical or ocular corticosteroids are not exclusionary.
- •Has another medical condition that requires an immunosuppressive agent unless the medication has been used for at least 6 months, the dose has been stable for at least 3 months prior to baseline and the medication and the dose are expected to remain stable during the study.
- •Has previously received nipocalimab.
- •Has any confirmed or suspected clinical immunodeficiency syndrome not related to treatment of his/her gMG, or has a family history of congenital or hereditary immunodeficiency unless confirmed absent in the participant. (Note: Participants should not be actively deteriorating at the screening or baseline visit such that they meet the criteria for Clinical Deterioration)
- •Has had a BCG vaccination within 1 year of first administration of study intervention.
- •Additional Exclusion criteria are included in the protocol.
- •Has MGFA Class I disease or presence of MG crisis (MGFA Class V) at screening, history of MG crisis within 1 month of screening, or fixed weakness (and/or 'burnt out' MG).
- •Is dependent on gastric tube for nutritional needs or is ventilator dependent.
- •Is actively undergoing radiation or chemotherapy for an unresected thymoma/malignant thymoma. Participants with stable, benign thymoma (stage I or IIa, for example) for which no treatment has been undertaken in the past 3 years may be allowed following discussion with the sponsor's medical monitor.
- •Has had a thymectomy within 12 months prior to screening, or thymectomy is planned during the Active treatment Phase of the study.
- •Has current or a history of any neurologic disorder other than MG that might interfere with the accuracy of study assessments, including but not limited to any chronic neurodegenerative disease, altered level of consciousness, dementia, abnormal mental status, major congenital neurologic defect, Lambert-Eaton myasthenic syndrome, drug induced MG, or hereditary forms of myasthenia syndrome.
- •Currently has a malignancy or has a history of malignancy within 3 years before screening (with the exception of localized basal cell carcinoma and/or squamous cell carcinoma skin cancer that has been adequately treated with no evidence of recurrence for at least 3 months [defined as a minimum of 12 weeks] before the first study intervention administration or cervical carcinoma in situ that has been treated with no evidence of recurrence for at least 3 months before the first study intervention administration).
- •Has known allergies, hypersensitivity, or intolerance to nipocalimab or its excipients (refer to the IB).
结局指标
主要结局
The effect of nipocalimab on total serum IgG in pediatric participants 2 to <18 years of age with gMG who have an insufficient clinical response to ongoing, stable standard-of-care therapy.
The effect of nipocalimab on total serum IgG in pediatric participants 2 to <18 years of age with gMG who have an insufficient clinical response to ongoing, stable standard-of-care therapy.
The safety and tolerability of treatment with nipocalimab in pediatric participants 2 to <18 years of age with gMG who have an insufficient clinical response to ongoing, stable standardof- care therapy.
The safety and tolerability of treatment with nipocalimab in pediatric participants 2 to <18 years of age with gMG who have an insufficient clinical response to ongoing, stable standardof- care therapy.
The pharmacokinetics of nipocalimab in pediatric participants 2 to <18 years of age with gMG who have an insufficient clinical response to ongoing, stable standard of care therapy.
The pharmacokinetics of nipocalimab in pediatric participants 2 to <18 years of age with gMG who have an insufficient clinical response to ongoing, stable standard of care therapy.
All primary PK and IgG endpoints will be summarized descriptively over time for the evaluable population, and for each age cohort (2 to <12, or 12 to <18 years old).
All primary PK and IgG endpoints will be summarized descriptively over time for the evaluable population, and for each age cohort (2 to <12, or 12 to <18 years old).
次要结局
未报告次要终点
研究者
CTIS Point of Contact
Scientific
Janssen - Cilag International
研究点 (2)
Loading locations...
相似试验
招募中
3 期
Comparative Efficacy of Nipocalimab and Efgartigimod in Myasthenia Gravis Study ID: 80202135MYG3002 EPIC2025-521130-28-00Janssen Cilag International7
招募中
3 期
Double-blind, Randomized, Placebo-controlled Study Evaluating the Safety and Efficacy of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) in At-risk Pregnancies2023-504307-88-00Janssen - Cilag International23
招募中
3 期
A Study of Efficacy, Safety, and Pharmacokinetics of Guselkumab in the Treatment of Chronic Plaque Psoriasis in Pediatric Participants2023-503378-19-00Janssen - Cilag International97
已完成
2 期
A Study of Nivolumab and Nivolumab Combinations in Recurrent and Metastatic Colon Cancer2024-516004-42-01Bristol Myers Squibb International Corporation143
尚未招募
3 期
An Open-label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of 12-month Treatment with Migalastat in Pediatric Subjects (aged 2 to < 12 years) with Fabry Disease and Amenable GLA VariantsFabry disease2025-521244-38-00Amicus Therapeutics Inc.1